Subjects will receive tazemetostat as dictated in their antecedent study.
Conditions
Brief summary
Number of subjects with adverse events related to study drug, as a measure of safety and tolerability of tazemetostat, Number of subjects with adverse events, as a measure of safety and tolerability of tazemetostat, Extent of exposure to tazemetostat
Detailed description
The OS of subjects receiving tazemetostat, defined as the interval of time between the date of the first dose of tazemetostat and the date of death due to any cause
Interventions
None listed
Sponsors
Epizyme Inc.
Eligibility
Sex/Gender
All
Age
0 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of subjects with adverse events related to study drug, as a measure of safety and tolerability of tazemetostat, Number of subjects with adverse events, as a measure of safety and tolerability of tazemetostat, Extent of exposure to tazemetostat | — |
Secondary
| Measure | Time frame |
|---|---|
| The OS of subjects receiving tazemetostat, defined as the interval of time between the date of the first dose of tazemetostat and the date of death due to any cause | — |
Countries
France, Poland
Outcome results
None listed